Abstract
Background Pandemic of coronavirus disease-2019 (COVID-19) puts a heavy burden not only on patients’ physical and mental health but also on regional health care resource and economic activity across the world. Although we accumulate incidence rate and case fatality rate by the multidisciplinary approach, epidemiological data of prevalence of serum severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) antibody in health-care workers during COVID-19 peri-pandemic period is insufficient.
Methods We prospectively recruited health-care workers from our hospital between April 10 and April 20, 2020. We collected serum samples from these participants and evaluated quantitative SARS-CoV-2 IgG antibody by enzyme-linked immunosorbent assay.
Results Five (5.4%), 15 (16.3%) and 72 (78.3%) participants showed positive, borderline and negative results of the serum SARS-CoV-2 IgG antibody, respectively. We found mean titer of the antibody levels of all, positive group, borderline group and negative group were clearly distinguished. Participants belonging to otolaryngology ward and/or having a history of seasonal common cold symptoms had significantly higher titer of SARS-CoV-2 IgG antibody (p=0.046, p=0.046, respectively).
Conclusions Five (5.4%) and 15 (16.3%) participants showed positive and borderline SARS-CoV-2 IgG antibody during COVID-19 peri-pandemic period. These rates were much higher than the rates expected from situation reports of the government. Higher rates of positive and borderline antibody suggested that COVID-19 had already spread at early stage of pandemic in the southern part of Kyoto city.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by National Hospital Organization annual fiduciary funds.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data of this study is available for anyone if our institute IRB allows.
